Stakeholder Mapping Sample Clauses

The Stakeholder Mapping clause defines the process for identifying and documenting all parties who have an interest in or are affected by a project or agreement. Typically, this involves creating a list or matrix that details each stakeholder's role, level of influence, and specific interests or concerns related to the project. By systematically mapping stakeholders, the clause ensures that communication and engagement strategies can be tailored appropriately, ultimately helping to manage expectations and reduce the risk of misunderstandings or overlooked interests during the course of the project.
Stakeholder Mapping. The aim of this will be to ensure that all the stakeholders likely to be affected or influence the Project are identified and targeted as part of the ESIA study. The following stakeholders are necessary and require to be engaged in the ESIA study, they include;-
View SourceView Similar (3)
Stakeholder Mapping. Stakeholder mapping is an essential and basic step complementing the communication activities of the PLATOON project. In the process we identify the individuals and groups that are likely to affect or be affected by our proposed actions and results. Then, we group them based on their impact and interest factors on the actions as well as the impact the actions may have on them. By assessing this information, the consortium gets a clearer vision on how the interests of those stakeholders should be addressed both in the project communication and dissemination plan as well as relevant activities. The following project stakeholders are identified and categorized in connection to the PLATOON project based on the figure below:
View Source
Stakeholder Mapping. All TSOs.
View Source
Stakeholder Mapping. A stakeholder mapping will be carried out, monitored, and updated throughout the course of the project to identify the most relevant players in the target groups defined above. An initial list will be created starting from contacts from Project Consortium partners' networks belonging to identified stakeholder groups. As WP6 leader, EHPA will actively disseminate the project objectives, activities, and results within EHPA Research and Innovation Committee. The R&I Committee has more than 110 and provides an opportunity to share information on HP Research and Innovation. The initiative's goal is to establish a group and promote synergies between group members. PUSH2HEAT will be disseminated during the periodic meetings of the committee to grow its outreach. In addition, EHPA will introduce PUSH2HEAT in the EHPA Manufacturers Committee (MCO). This committee has more than 100 members and aims to provide a platform for manufacturers in the association to discuss topics relevant to manufacturers. It defines and suggests areas of strategic interest to the manufacturers. Presenting the project during one of the MCO periodic meetings could add value to the project and the MCO members. It would contribute to expanding the stakeholder network of the project and therefore, increase the transferability of the outcomes.
View Source
Stakeholder Mapping. Developer shall identify and categorize the various individuals, groups, and organizations that have an interest or stake in the project or are affected by it. Stakeholders can include residents, local businesses, community leaders, houses of worship, nonprofits, government agencies, utilities and Common Choice Aggregators, and other relevant entities.
View Source
Stakeholder Mapping. Potential stakeholders for the project results can be found from all parts of the value chain throughout the lifecycle of the REFCS. From operation perspective, these range from fuel feedstock suppliers to the customers using the produced electricity. Taking into account the system manufacturing, an even broader scope is established, starting from raw material extraction to system integrators and recycling of the components. The following sections describe the potential stakeholders, divided by industrial and other economic sectors. In addition, the geographical division of the potential stakeholder types is presented. 4.1 Fuel processing and distribution As most of the fuel processing plants are designed for production of very pure bioethanol, upscaling of the crude bioethanol production, yielding lower retail prices, may not be in direct interest of the distilleries. However, with the fractional distillation process, for a portion of high quality pure bioethanol, a portion of low quality bioethanol is also produced. As markets for low quality bioethanol are currently very limited, fuel processing industry will benefit of the increased sales of this fraction. Another sector, slowly emerging, includes companies establishing hydrogen distribution networks based on hydrogen refuelling stations (HRS), mainly for dispensing hydrogen for use as fuel in transport applications. This sector will be very interested on the possibility on- site production of hydrogen from bioethanol. Exchanging information on hydrogen buffer tank solutions and end user requirements within the project also serves these stakeholders. 4.2 Electricity supply and security, industrial end users
View Source

Related to Stakeholder Mapping

  • Access Toll Connecting Trunk Group Architecture 9.2.1 If WCS chooses to subtend a Verizon access Tandem, WCS’s NPA/NXX must be assigned by WCS to subtend the same Verizon access Tandem that a Verizon NPA/NXX serving the same Rate Center Area subtends as identified in the LERG. 9.2.2 WCS shall establish Access Toll Connecting Trunks pursuant to applicable access Tariffs by which it will provide Switched Exchange Access Services to Interexchange Carriers to enable such Interexchange Carriers to originate and terminate traffic to and from WCS’s Customers. 9.2.3 The Access Toll Connecting Trunks shall be two-way trunks. Such trunks shall connect the End Office WCS utilizes to provide Telephone Exchange Service and Switched Exchange Access to its Customers in a given LATA to the access Tandem(s) Verizon utilizes to provide Exchange Access in such LATA. 9.2.4 Access Toll Connecting Trunks shall be used solely for the transmission and routing of Exchange Access to allow WCS’s Customers to connect to or be connected to the interexchange trunks of any Interexchange Carrier which is connected to a Verizon access Tandem.

  • COVID-19 Vaccinations Contractor understands, acknowledges, and agrees that, pursuant to Article II of the General Appropriations Act, none of the General Revenue Funds appropriated to the Department of State Health Services (DSHS) may be used for the purpose of promoting or advertising COVID-19 vaccinations in the 2024-25 biennium. It is also the intent of the legislature that to the extent allowed by federal law, any federal funds allocated to DSHS shall be expended for activities other than promoting or advertising COVID-19 vaccinations. Contractor represents and warrants that it is not ineligible, nor will it be ineligible during the term of this Contract, to receive appropriated funding pursuant to Article II.

  • Information Technology Enterprise Architecture Requirements If this Contract involves information technology-related products or services, the Contractor agrees that all such products or services are compatible with any of the technology standards found at ▇▇▇▇▇://▇▇▇.▇▇.▇▇▇/iot/2394.htm that are applicable, including the assistive technology standard. The State may terminate this Contract for default if the terms of this paragraph are breached.

  • Safety Boots Each employee, after 3 months’ continuous service, will be reimbursed (on production of a receipt), the cost of one pair of safety boots (approved by the employer), in each year, to a maximum of $110.00. All protective clothing such as wet weather jackets, safety helmets, welding jackets, welding ▇▇▇▇▇▇▇, welding gauntlets, rubber boots, etc, (which remain the property of the Company), will be supplied on all occasions deemed necessary.

  • Clinical Data and Regulatory Compliance The preclinical tests and clinical trials, and other studies (collectively, “studies”) that are described in, or the results of which are referred to in, the Registration Statement or the Prospectus were and, if still pending, are being conducted in all material respects in accordance with the protocols, procedures and controls designed and approved for such studies and with standard medical and scientific research procedures; each description of the results of such studies is accurate and complete in all material respects and fairly presents the data derived from such studies, and the Company and its subsidiaries have no knowledge of any other studies the results of which are inconsistent with, or otherwise call into question, the results described or referred to in the Registration Statement or the Prospectus; the Company and its subsidiaries have made all such filings and obtained all such approvals as may be required by the Food and Drug Administration of the U.S. Department of Health and Human Services or any committee thereof or from any other U.S. or foreign government or drug or medical device regulatory agency, or health care facility Institutional Review Board (collectively, the “Regulatory Agencies”); neither the Company nor any of its subsidiaries has received any notice of, or correspondence from, any Regulatory Agency requiring the termination, suspension or modification of any clinical trials that are described or referred to in the Registration Statement or the Prospectus; and the Company and its subsidiaries have each operated and currently are in compliance in all material respects with all applicable rules, regulations and policies of the Regulatory Agencies.